S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:GRCL

Gracell Biotechnologies Stock Competitors

$4.32
-0.13 (-2.92%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.03
$4.53
50-Day Range
$4.32
$11.53
52-Week Range
$4.03
$33.70
Volume
220,100 shs
Average Volume
229,879 shs
Market Capitalization
$291.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Gracell Biotechnologies (NASDAQ:GRCL) Vs. ENTA, NGM, INVA, CDMO, MDGL, KROS, MOR, ADCT, PRTC, and IMGN

Should you be buying Gracell Biotechnologies stock or one of its competitors? The main competitors of Gracell Biotechnologies include Enanta Pharmaceuticals (ENTA), NGM Biopharmaceuticals (NGM), Innoviva (INVA), Avid Bioservices (CDMO), Madrigal Pharmaceuticals (MDGL), Keros Therapeutics (KROS), MorphoSys (MOR), ADC Therapeutics (ADCT), PureTech Health (PRTC), and ImmunoGen (IMGN). These companies are all part of the "pharmaceutical preparations" industry.

Gracell Biotechnologies vs.

NGM Biopharmaceuticals (NASDAQ:NGM) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Gracell Biotechnologies has lower revenue, but higher earnings than NGM Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$87.37 million12.88-$102.49 million-$1.61-9.04
Gracell BiotechnologiesN/AN/A-$32.47 millionN/AN/A

NGM Biopharmaceuticals currently has a consensus target price of $35.00, suggesting a potential upside of 140.55%. Gracell Biotechnologies has a consensus target price of $34.50, suggesting a potential upside of 698.61%. Given Gracell Biotechnologies' higher probable upside, analysts clearly believe Gracell Biotechnologies is more favorable than NGM Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NGM Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Gracell Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

58.5% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 48.1% of Gracell Biotechnologies shares are owned by institutional investors. 45.9% of NGM Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NGM Biopharmaceuticals received 13 more outperform votes than Gracell Biotechnologies when rated by MarketBeat users. Likewise, 75.76% of users gave NGM Biopharmaceuticals an outperform vote while only 52.17% of users gave Gracell Biotechnologies an outperform vote.

CompanyUnderperformOutperform
NGM BiopharmaceuticalsOutperform Votes
25
75.76%
Underperform Votes
8
24.24%
Gracell BiotechnologiesOutperform Votes
12
52.17%
Underperform Votes
11
47.83%

Gracell Biotechnologies has a net margin of 0.00% compared to NGM Biopharmaceuticals' net margin of -157.90%. Gracell Biotechnologies' return on equity of 0.00% beat NGM Biopharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NGM Biopharmaceuticals -157.90% -34.43% -30.02%
Gracell Biotechnologies N/A N/A N/A

In the previous week, NGM Biopharmaceuticals had 2 more articles in the media than Gracell Biotechnologies. MarketBeat recorded 4 mentions for NGM Biopharmaceuticals and 2 mentions for Gracell Biotechnologies. Gracell Biotechnologies' average media sentiment score of 0.59 beat NGM Biopharmaceuticals' score of 0.09 indicating that Gracell Biotechnologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NGM Biopharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gracell Biotechnologies
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

NGM Biopharmaceuticals beats Gracell Biotechnologies on 9 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Gracell Biotechnologies (NASDAQ:GRCL) vs. Its Competitors

TypeGracell BiotechnologiesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$291.60M$5.72B$4.65B$6.90B
Dividend YieldN/A2.51%2.03%2.91%
P/E RatioN/A13.5217.2018.32
Price / SalesN/A473.585,753.63225.01
Price / CashN/A163.8261.4268.48
Price / Book-3.158.617.598.87
Net Income-$32.47M$99.39M$98.86M$156.27M
7 Day Performance-5.88%-9.05%-5.85%-6.56%
1 Month Performance-31.75%-17.94%-12.41%-10.43%
1 Year Performance-79.81%-33.32%-22.08%-12.14%

Gracell Biotechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTA
Enanta Pharmaceuticals
2.4681 of 5 stars
$56.49
-1.1%
$90.25
-59.8%
+20.7%$1.15B$97.07M-14.45141
NGM
NGM Biopharmaceuticals
2.3792 of 5 stars
$14.55
-1.9%
$35.00
-140.5%
-47.8%$1.13B$87.37M-9.04210Short Interest ↑
News Coverage
INVA
Innoviva
1.7165 of 5 stars
$16.17
-0.0%
N/A+31.4%$1.12B$336.79M5.185
CDMO
Avid Bioservices
2.4814 of 5 stars
$18.20
-1.7%
$31.67
-74.0%
+33.6%$1.12B$95.87M140.01255Gap Down
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$63.57
-2.7%
$177.57
-179.3%
-41.9%$1.09BN/A-4.3442
KROS
Keros Therapeutics
2.1665 of 5 stars
$46.30
-2.0%
$86.67
-87.2%
-28.0%$1.08B$10M-17.0835
MOR
MorphoSys
1.2032 of 5 stars
$7.90
-3.0%
$27.08
-242.8%
-73.5%$1.08B$374.30M-5.98615Gap Down
ADCT
ADC Therapeutics
1.9514 of 5 stars
$15.67
-0.1%
$45.20
-188.4%
-50.6%$1.08B$2.34M-4.78208Analyst Upgrade
News Coverage
PRTC
PureTech Health
1.3665 of 5 stars
$37.32
-4.5%
$71.00
-90.2%
-32.8%$1.07B$11.77M0.0066Gap Up
IMGN
ImmunoGen
1.8931 of 5 stars
$5.25
-5.1%
$9.50
-81.0%
-31.4%$1.06B$132.30M-15.4479Short Interest ↑
PROC
Procaps Group S.A
2.2417 of 5 stars
$9.13
-5.3%
$13.00
-42.4%
N/A$1.03B$106.83M0.00N/A
VAXX
Vaxxinity
1.825 of 5 stars
$8.16
-2.7%
$19.50
-139.0%
N/A$1.02B$560K0.002,021Gap Down
RCKT
Rocket Pharmaceuticals
2.3531 of 5 stars
$15.69
-4.1%
$65.25
-315.9%
-70.1%$1.01BN/A-5.11101
MRUS
Merus
1.7298 of 5 stars
$25.90
-0.5%
$40.20
-55.2%
-4.8%$1.01B$29.94M-11.16117
RVNC
Revance Therapeutics
2.3781 of 5 stars
$13.43
-4.5%
$23.60
-75.7%
-52.7%$964.21M$15.32M-2.99470Analyst Report
RETA
Reata Pharmaceuticals
2.4498 of 5 stars
$26.18
-4.1%
$85.00
-224.7%
-76.4%$952.74M$9.02M-3.39267Gap Down
MNKD
MannKind
1.6498 of 5 stars
$3.79
-3.7%
$6.30
-66.2%
+11.1%$952.26M$65.14M-11.84241
ORGO
Organogenesis
2.7998 of 5 stars
$7.31
-4.4%
$23.00
-214.6%
-26.8%$940.39M$338.30M15.89910Short Interest ↑
RANI
Rani Therapeutics
1.3798 of 5 stars
$18.88
-11.4%
$23.50
-24.5%
N/A$925.16MN/A0.002,021Lockup Expiration
DAWN
Day One Biopharmaceuticals
2.0265 of 5 stars
$14.63
-1.0%
$37.33
-155.2%
N/A$906.02MN/A0.0020Insider Buying
Short Interest ↑
News Coverage
Positive News
CRNX
Crinetics Pharmaceuticals
2.3448 of 5 stars
$18.97
-10.3%
$36.80
-94.0%
+26.5%$901.08M$70K-6.8293Gap Down
AXSM
Axsome Therapeutics
2.482 of 5 stars
$23.71
-12.7%
$89.22
-276.4%
-68.8%$893.49MN/A-7.0860Gap Down
High Trading Volume
ZEAL
Zealand Pharma A/S
0.8798 of 5 stars
$20.00
-3.3%
N/A-46.8%$872.68M$54.13M-4.61329Analyst Upgrade
Short Interest ↑
News Coverage
Gap Down
High Trading Volume
GHRS
GH Research
1.7464 of 5 stars
$17.19
-1.2%
$26.42
-53.7%
N/A$868.46MN/A0.008Short Interest ↑
News Coverage
ANAB
AnaptysBio
1.8531 of 5 stars
$30.99
-0.4%
$35.80
-15.5%
+23.5%$856.72M$75M110.6894News Coverage
HRTX
Heron Therapeutics
1.9248 of 5 stars
$8.38
-1.8%
$26.00
-210.3%
-52.4%$854.22M$88.64M-3.51223
NRIX
Nurix Therapeutics
2.2 of 5 stars
$19.11
-1.2%
$54.43
-184.8%
-56.6%$852.55M$17.82M-8.002,020
ATAI
Atai Life Sciences
2.1054 of 5 stars
$5.26
-5.5%
$29.67
-464.0%
N/A$843.17MN/A0.0035Analyst Report
QURE
uniQure
2.4264 of 5 stars
$18.03
-1.3%
$59.31
-228.9%
-53.3%$833.24M$37.51M2.65332Short Interest ↑
CNTA
Centessa Pharmaceuticals
2.1398 of 5 stars
$8.99
-1.3%
$38.00
-322.7%
N/A$808.21MN/A0.002,021News Coverage
PAHC
Phibro Animal Health
2.4498 of 5 stars
$19.95
-0.8%
$23.00
-15.3%
-6.4%$808.06M$833.40M16.631,725
SNDX
Syndax Pharmaceuticals
1.7214 of 5 stars
$16.12
-4.0%
$27.00
-67.5%
-24.3%$796.20M$1.52M-8.8643Analyst Upgrade
VNDA
Vanda Pharmaceuticals
2.4814 of 5 stars
$14.19
-2.0%
$20.00
-40.9%
-2.5%$790.55M$248.17M23.26292
GOSS
Gossamer Bio
2.4131 of 5 stars
$10.29
-3.7%
$23.00
-123.5%
+1.3%$786.82MN/A-3.16196Gap Down
KURA
Kura Oncology
1.6331 of 5 stars
$11.78
-0.1%
$40.00
-239.6%
-65.6%$784.03MN/A-6.1489News Coverage
High Trading Volume
MGNX
MacroGenics
2.3464 of 5 stars
$12.71
-1.5%
$34.29
-169.8%
-43.1%$778.59M$104.88M-5.30370
ARQT
Arcutis Biotherapeutics
2.4131 of 5 stars
$15.40
-1.6%
$55.25
-258.8%
-43.4%$774.54MN/A-4.3654
PMVP
PMV Pharmaceuticals
2.3648 of 5 stars
$16.80
-1.7%
$53.67
-219.4%
-61.8%$762.38MN/A6.3444Short Interest ↑
News Coverage
ENDP
Endo International
2.0898 of 5 stars
$3.21
-3.4%
$6.20
-93.1%
-52.9%$750.08M$2.90B11.463,397Short Interest ↑
Gap Down
VTYX
Ventyx Biosciences
2.325 of 5 stars
$14.85
-2.8%
$43.33
-191.8%
N/A$746.91MN/A0.00N/AAnalyst Downgrade
News Coverage
TNGX
Tango Therapeutics
2.0381 of 5 stars
$8.30
-3.5%
$16.50
-98.8%
N/A$726.63MN/A0.004News Coverage
EWTX
Edgewise Therapeutics
1.9215 of 5 stars
$14.59
-0.3%
$34.00
-133.0%
N/A$719.23MN/A0.0019Short Interest ↑
Gap Down
KNSA
Kiniksa Pharmaceuticals
2.1781 of 5 stars
$10.37
-2.7%
$30.67
-195.7%
-40.6%$714.37MN/A-4.05168
AKRO
Akero Therapeutics
2.0098 of 5 stars
$19.93
-0.4%
$52.33
-162.6%
-33.3%$695.32MN/A-7.0722Insider Selling
MCRB
Seres Therapeutics
1.9798 of 5 stars
$7.51
-1.5%
$19.20
-155.7%
-68.9%$689.77M$33.22M-19.76155Analyst Downgrade
News Coverage
PRAX
Praxis Precision Medicines
2.0333 of 5 stars
$15.00
-3.5%
$40.33
-168.9%
-72.3%$672.84MN/A-4.342,020Short Interest ↑
Gap Down
RNA
Avidity Biosciences
2.2198 of 5 stars
$14.22
-3.4%
$49.60
-248.8%
-46.8%$666.88M$6.79M-5.8082
STOK
Stoke Therapeutics
2.3388 of 5 stars
$18.10
-0.2%
$52.50
-190.1%
-73.2%$665.92MN/A-8.6679News Coverage
CMPS
COMPASS Pathways
1.9 of 5 stars
$15.77
-3.4%
$79.86
-406.4%
-64.9%$658.10MN/A-9.332,020
AMYT
Amryt Pharma
1.9917 of 5 stars
$10.27
-0.3%
$29.50
-187.2%
-26.6%$656.90M$182.61M-21.402,020Analyst Downgrade
Short Interest ↓
Gap Down
This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.